Assess whether scientific advice should be sought before the next trial

Situation

Labeling negotiator in a 505(b)(2) program relying on literature plus a bridging study has one working extract — phase-3 protocol with endpoint-sensitivity issues — after an inspector asking for batch records you cannot produce this week. If phase-3 protocol with endpoint-sensitivity issues cannot support scientific advice should be, the honest Pharma & Life Sciences output is hold.

Decision

Labeling negotiator in a 505(b)(2) program relying on literature plus a bridging study must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using phase-3 protocol with endpoint-sensitivity issues after an inspector asking for batch records you cannot produce this week.

Hypotheses to test

• Authorize Proceed under protocol now; phase-3 protocol with endpoint-sensitivity issues already has the discriminator after an inspector asking for batch records you cannot produce this week.
• Keep Pause the pathway in force until phase-3 protocol with endpoint-sensitivity issues is completed after an inspector asking for batch records you cannot produce this week for labeling negotiator.
• Treat phase-3 protocol with endpoint-sensitivity issues as Escalate safety review because both readings appear after an inspector asking for batch records you cannot produce this week.
• Refuse a Pharma & Life Sciences close: labeling negotiator does not have the page scientific advice should be turns on in phase-3 protocol with endpoint-sensitivity issues.

Analysis required

• Separate an isolated adverse event from a systemic quality issue.
• Test a protocol deviation versus a safety signal versus a filing gap on scientific advice should be.
• Check whether phase-3 protocol with endpoint-sensitivity issues supports the labeled claim labeling negotiator would keep.
• For this Pharma & Life Sciences CMC and Development Pathways file, read phase-3 protocol with endpoint-sensitivity issues against an inspector asking for batch records you cannot produce this week and write the one fact that would move scientific advice should be for labeling negotiator.

Recommendation

Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / CMC and Development Pathways packet (phase-3 protocol with endpoint-sensitivity issues after an inspector asking for batch records you cannot produce this week). Lead with the Pharma & Life Sciences option phase-3 protocol with endpoint-sensitivity issues can support after an inspector asking for batch records you cannot produce this week, then the two facts that force it, then the Monday action for labeling negotiator in a 505(b)(2) program relying on literature plus a bridging study.